



May 21, 2026

To whom it may concern:

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Hidetoshi Segi, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL: +81-6-6758-8223)

Notice of Dividend of Surplus

ROHTO PHARMACEUTICAL CO., LTD. are pleased to announce the resolution made at the Board of Directors meeting held today to pay dividends from retained earnings with a record date of March 31, 2026, as follows.

Details of dividends

	Determined amount	Most recent dividend forecast (Announced on May 13, 2026)	Results for the previous fiscal year (Year ended March 31, 2025)
Record date	March 31, 2026	Same as left	March 31, 2025
Year-end dividend per share	25yen	25yen	20yen
Total dividends	5,649million yen	5,649 million yen	4,519 million yen
Effective date	Jun 8, 2026	—	Jun 12, 2025
Sources	Retained earnings	—	Retained earnings

(Reference) Breakdown of Annual Dividends

Record date	Dividend per share		
	2nd quarter-end	Year-end	Total
Results for the previous fiscal year (Year ended March 31, 2025)	16yen	20yen	36yen
Results for the fiscal year under review	21yen	25yen	46yen
Forecast for the coming year (Year ended March 31, 2027)	25yen	25yen	50yen